In our study, the NFS performed well in identifying patients
with and without advanced fibrosis in the entire group. However subgroup
analysis suggested that the utility of the NFS had divergent clinical
reliability for NAFLD patients with and without DM, particularly in
excluding advanced fibrosis in patients without DM although this
must be tampered in the context of a relatively lower prevalence of advanced
fibrosisamong the non-DMpatients. Larger studies arewarranted
to clarify the utility of the NFS in non-DM patients with NAFLD.